cervical cancer · most optimistic projection for the technology a broadly applicable, “off the...
TRANSCRIPT
Cervical Cancer
Cancers attributable to HPV
HPV cancers
HIV genome
Virion
HPV life cycle
HPV infection
Cervical cancer
HPV carcinogenesis
Cellular proteins
HPV pathways
HPV infection time line
HPV infection
Pap screening
Primary prevention
Virus like particles
Three vaccines
Timeline of HPV Association
Precursor Lesions
Efficacy of HPV Vaccine
Gardasil-9
Clinical Trial Evidence
Protection from Initial Infection
HPC vaccine
Safety record
Vaccine effectiveness
Vaccination
Reduction of CIN2+ cervical dysplasia
Prevention of cervical cancer
HPV vaccines
Non-vaccine scenario
Worldvide HPV vaccine uptake
US girls vaccination rate
Increasing Uptake, Particularly in Low Resource Settings
Post hoc analysis
One dose clinical trial results
Single dose HPV vaccination
One or two doses of the HPV vaccine
Why do HPV VLP vaccines work so well?
Antibody responses to VLPs
Persistence of antibodies
Durability of VLP Ab response
VLP Ab response
B cells recognize dense repetitive protein arrays
Repetitive antigen display
Vaginal HPV infection
Cervix Ab response
Antibody titers and protection
Passive transfer
Gardasil sera protection
Mechanisms of in vivo infection
Conclusions
Exploiting HPV’s unexpected infection mechanism
Binding to divergent tissue types
VLPs bind to most tumor cell lines
Can HPV infect tumors in vivo?
HPV capsids for cancer
HPV VLP-IR700 conjugates
Occular/uveal melanoma
Xenograft model of uveal melanoma
Xenograft model of uveal melanoma
Clinical trial of uveal melanoma
Preliminary clinical trial results
Most optimistic projection for the technology
A broadly applicable, “off the shelf” cancer therapy. What cancer should be tried next?
Key Collaborators